Glycolipid nanoparticles and therapeutic uses
Glycolipid nanoparticles with specific compositions target the spleen and reduce liver accumulation, addressing the liver concentration issue of traditional lipid nanoparticles, achieving targeted delivery to specific tissues.
WO2026117444A1PCT designated stage Publication Date: 2026-06-04EMORY UNIVERSITY
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- EMORY UNIVERSITY
- Filing Date
- 2025-11-20
- Publication Date
- 2026-06-04
Smart Images
Figure US2025056483_04062026_PF_FP_ABST
Abstract
This disclosure relates to compositions comprising glycolipid nanoparticles and a therapeutic comprising: a) ionizable lipid, b) poly(ethylene glycol) lipid, c) sterol, and d) glycolipid. In certain embodiments, the average diameter of the particles is about between 30 and 180 nm. In certain embodiments, the therapeutic is a nucleic acid encoding a therapeutic protein.
Need to check novelty before this filing date? Find Prior Art